Profile data is unavailable for this security.
About the company
Tsumura & Co is a Japan-based company mainly engaged in manufacturing and sales of prescription drugs and over-the-counter drugs. The Company operates the Pharmaceuticals segment. In Japan, the Company conducts the manufacturing, sales, transportation and storage of prescription drugs and over-the-counter drugs, and cultivation, procurement, selection, processing and storage of raw medicinal herbs. In China, the Company is engaged in regional management, business management, production and sales of herbal extract powders, cultivation, procurement, selection, processing and storage of herbal ingredients, and sales of pharmaceuticals and food products. In Laos, the Company is engaged in cultivation, procurement, selection, processing and storage of herbal ingredients. In the United States, the Company is engaged in pharmaceutical development business.
- Revenue in JPY (TTM)189.50bn
- Net income in JPY29.01bn
- Incorporated1936
- Employees4.27k
- LocationTsumura & Co2-17-11, AkasakaMINATO-KU 107-8521JapanJPN
- Phone+81 363617121
- Websitehttp://www.tsumura.co.jp
More ▼
Mergers & acquisitions
| Acquired company | 4540:TYO since announced | Transaction value |
|---|---|---|
| YOMEISHU SEIZO CO LTD | -0.27% | -- |
Data delayed at least 15 minutes, as of Feb 13 2026 06:30 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr | 31.12bn | 8.52bn | 298.55bn | 1.10k | 35.03 | 1.49 | 26.09 | 9.59 | 3.55 | 3.55 | 12.98 | 83.78 | 0.1393 | 3.47 | 5.91 | 8,173,382.00 | 3.81 | 6.40 | 4.07 | 6.86 | 26.87 | 33.31 | 27.39 | 40.47 | 1.87 | -- | 0.0602 | 27.65 | -6.28 | 58.48 | -74.12 | 44.46 | 151.56 | 88.80 |
| Ocular Therapeutix Inc | 7.94bn | -40.62bn | 301.26bn | 325.00 | -- | 2.99 | -- | 37.96 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| Tibet Rhodiola Pharmaceutical Holding Co | 60.21bn | 21.72bn | 302.27bn | 596.00 | 13.93 | 3.85 | -- | 5.02 | 3.04 | 3.04 | 8.44 | 11.02 | 0.5188 | 1.38 | 6.52 | 4,564,666.00 | 18.84 | 14.99 | 25.61 | 19.30 | 92.08 | 92.11 | 36.31 | 23.95 | 2.89 | -- | 0.1971 | 52.89 | -10.45 | 17.45 | 31.26 | 27.47 | -5.16 | 27.43 |
| Perrigo Company PLC | 654.02bn | -4.46bn | 302.29bn | 8.38k | -- | 0.445 | 6.54 | 0.4622 | -0.2128 | -0.3764 | 31.00 | 32.31 | 0.4023 | 2.34 | 5.75 | 511,015.60 | -0.2743 | -0.7059 | -0.3124 | -0.8082 | 35.46 | 34.96 | -0.682 | -1.76 | 1.44 | 2.41 | 0.4505 | -- | -6.06 | 2.48 | -3,552.27 | -- | -16.23 | 18.65 |
| Bora Pharmaceuticals Co Ltd | 96.76bn | 22.34bn | 303.46bn | 91.00 | 14.37 | 5.36 | 10.77 | 3.14 | 34.10 | 24.33 | 143.28 | 91.50 | 0.4537 | 2.76 | 2.11 | -- | 10.60 | 11.35 | 16.48 | 18.81 | 39.99 | 39.47 | 23.36 | 19.44 | 1.07 | -- | 0.5549 | 37.72 | 35.53 | 65.95 | 29.99 | 66.80 | -0.3363 | 74.57 |
| FAES Farma SA | 103.01bn | 19.05bn | 303.88bn | 756.00 | 15.77 | -- | 13.00 | 2.95 | 0.336 | 0.336 | 1.82 | -- | -- | -- | -- | 320,062.00 | -- | 13.17 | -- | 15.13 | 65.15 | 64.65 | 18.49 | 20.72 | -- | 155.55 | -- | -- | 9.42 | 6.67 | 21.17 | 11.73 | 13.09 | -- |
| Tsumura & Co | 189.50bn | 29.01bn | 310.10bn | 4.27k | 10.44 | 0.9863 | 7.27 | 1.64 | 387.15 | 387.15 | 2,524.84 | 4,095.99 | 0.374 | 0.7106 | 2.41 | 44,357,680.00 | 6.01 | 5.53 | 8.06 | 6.85 | 47.60 | 49.39 | 16.06 | 14.50 | 1.45 | -- | 0.2856 | 31.65 | 20.05 | 8.00 | 94.10 | 18.69 | 23.07 | 16.27 |
| Fagron NV | -18.13tn | -18.13tn | 313.23bn | 3.99k | -- | 3.12 | -- | -- | -- | -- | -- | 7.51 | -- | -- | -- | -- | -- | 7.72 | -- | 9.52 | -- | 44.06 | -- | 9.75 | 1.39 | -- | 0.457 | 20.58 | 9.20 | 11.36 | 12.99 | 8.84 | 10.69 | 17.32 |
| Harmony Biosciences Holdings Inc | 126.16bn | 28.36bn | 315.39bn | 246.00 | 11.29 | 2.47 | 9.85 | 2.50 | 3.18 | 3.18 | 14.13 | 14.50 | 0.7732 | 26.70 | 9.07 | -- | 17.38 | 15.64 | 21.20 | 19.13 | 77.70 | 79.78 | 22.48 | 20.61 | 3.72 | -- | 0.1679 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
| Phibro Animal Health Corp | 223.67bn | 14.07bn | 317.41bn | 2.48k | 22.73 | 6.24 | 14.55 | 1.42 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
| Shanghai Shyndec Pharmaceutical Co Ltd | 205.06bn | 20.59bn | 319.11bn | 11.47k | 15.50 | 1.06 | -- | 1.56 | 0.6936 | 0.6936 | 6.91 | 10.17 | 0.4703 | 2.95 | 7.65 | 807,583.30 | 5.41 | 5.14 | 7.83 | 8.21 | 33.20 | 40.86 | 11.50 | 7.82 | 2.62 | -- | 0.003 | 20.02 | -9.38 | -2.16 | 56.62 | 10.55 | -11.46 | 24.57 |
Data as of Feb 13 2026. Currency figures normalised to Tsumura & Co's reporting currency: Japanese Yen JPY
29.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Marathon Asset Management Ltd.as of 15 Jul 2025 | 6.67m | 8.69% |
| Nomura Asset Management Co., Ltd.as of 14 Nov 2025 | 3.80m | 4.95% |
| Invesco Asset Management (Japan) Ltd.as of 15 Aug 2024 | 3.38m | 4.40% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 2.47m | 3.22% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 1.30m | 1.69% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 1.17m | 1.53% |
| Amova Asset Management Co., Ltd.as of 09 Jan 2026 | 1.03m | 1.34% |
| Daiwa Asset Management Co. Ltd.as of 30 Dec 2025 | 960.00k | 1.25% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 842.60k | 1.10% |
| Baillie Gifford & Co.as of 31 Jan 2026 | 677.90k | 0.88% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
